Browse the evidence

Obesity is a disease that results in impaired quality of life and reduced life expectancy.

Healthcare practitioners should recognize obesity as a disease and address its impacts on quality of life and longevity.

Two-thirds of obesity-related excess mortality is attributable to cardiovascular disease.

Public health initiatives should focus on reducing obesity to lower cardiovascular disease mortality.

Obesity has been underrecognized and sub-optimally addressed compared to other cardiovascular risk factors.

Healthcare providers should prioritize the recognition and management of obesity as a key cardiovascular risk factor.

Metformin is the most studied pharmacological treatment for the prevention and treatment of PDWG.

Metformin may be a viable option for managing weight gain associated with psychiatric medications.

Most relative risks (RRs) for protective associations ranged from 0.87 to 0.96 per daily serving change, while harmful associations ranged from 1.06 to 1.15 per daily serving change.

Understanding these RRs can help in making informed dietary choices to mitigate CMD risk.

Most identified associations were protective (n = 38) and a smaller number were harmful (n = 24), with a higher risk associated with higher intake.

Emphasizing protective dietary factors can aid in reducing CMD risk.

Twins on the vegan diet had a significant mean decrease in fasting insulin level of -2.9 μIU/mL after 8 weeks.

Clinicians may consider a vegan diet to improve insulin sensitivity in patients.

Age-related loss of muscle mass, strength, and performance, known as sarcopenia, has serious implications for morbidity and mortality.

Understanding the health risks associated with sarcopenia can guide interventions.

Anabolic resistance is implicated in the progression of age-related muscle loss and its complications.

Addressing anabolic resistance may help mitigate muscle loss in aging populations.

Food insecurity is a powerful social determinant of health that impacts health outcomes.

Addressing food insecurity is crucial for improving health outcomes.

Nutrition insecurity is a direct determinant of health.

Practitioners should recognize nutrition insecurity as a critical health factor.

Discontinuing GLP-1RA treatment leads to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those prescribed semaglutide/tirzepatide.

Practitioners should consider the likelihood of weight regain when discontinuing GLP-1RA therapy.

The proportion of weight regained after discontinuation of GLP-1RA therapy is proportional to the amount originally lost.

Weight loss strategies should account for the likelihood of proportional weight regain after stopping GLP-1RA therapy.

Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions.

Clinicians should inform patients that stopping GLP-1RA may lead to weight regain despite lifestyle efforts.

Lean mass remained stable in some cases, but notable reductions were observed in others, ranging from almost 0% to 40% of total weight reduction.

Clinicians should monitor lean mass changes in patients using semaglutide, as results can vary significantly.

Endoscopic sleeve gastroplasty (ESG) is more cost-effective than semaglutide over a 5-year time horizon, with an incremental cost-effectiveness ratio (ICER) of -$595,532/QALY.

Practitioners may consider ESG as a more cost-effective option for treating class II obesity compared to semaglutide.

GLP-1 receptor agonists (semaglutide, liraglutide) significantly improve cardiovascular biomarkers—including hs-CRP, systolic blood pressure, and lipid profiles—independent of glycemic control.

GLP-1 medications like semaglutide do more than just help you lose weight; they directly improve your heart health markers. They significantly lower systemic inflammation (hs-CRP), improve blood vessel function, lower blood pressure, and improve lipid profiles. These benefits happen even if you don't have diabetes, proving the drug protects your blood vessels directly. You should be aware of the slightly increased risk of gallbladder issues due to rapid weight loss, so your doctor will monitor your baseline risk.

Over 10 years, the MTM intervention is anticipated to potentially be associated with 18,257,000 averted hospitalizations and reductions in health care expenditures of $484.5 billion.

Long-term implementation of MTMs could significantly reduce hospitalizations and healthcare costs.

GLP1-RA treatment is associated with improvements in mental health-related quality of life compared with placebo (g = 0.15; P < .001).

GLP1-RAs may enhance mental health quality of life in this population.

There are quantitative sex differences in the response to GLP-1 and its analogs.

Practitioners should consider sex differences when prescribing GLP-1 analogs.

The share of prescriptions for semaglutide (Wegovy) increased to 27.7% among advanced practice practitioners (APPs) by February 2024.

Practitioners should consider the growing preference for semaglutide in obesity treatment.

The study of exercise as a preventative or therapeutic treatment is increasingly interdisciplinary and impactful.

Researchers and practitioners should collaborate across disciplines to enhance exercise interventions.

Vegan diets can be health-promoting and may offer certain important advantages compared to typical Western eating patterns.

Health professionals should recognize the potential health benefits of vegan diets.

A precise and practical vegan nutrition guide for health professionals is lacking.

There is an urgent need for health professionals to have access to a vegan nutrition guide.